Author

admin

Browsing

The first quarter of 2024 witnessed a surge in initial public offerings (IPOs) and mergers and acquisitions (M&A) within the biotech industry, signaling continued interest from investors. AstraZeneca’s acquisition of start-up Amolyt on March 14, and its longtime biotech partner Fusion Pharmaceuticals for US$2.4 billion on March 19 marked the…